Indications

• I3C may be used in the prevention and treatment of estrogen-dependent breast, colon, endometrial, cervical and prostate cancers;
• I3C may be used in the prevention and treatment of HSV and HPV infections;
• I3C may be used to support healthy estrogen and androgen metabolism.

Ingredients

Each capsule contains:
Indole-3-carbinol 150 mg

Contains no: Preservatives, artificial flavour or colour, sugar, dairy, wheat, gluten, corn or yeast.

Description

Indole-3-carbinol (I3C) is a phytochemical derived in high concentrations from the Brassica family of vegetables, including broccoli, cauliflower, Brussels sprouts and cabbage. I3C and its derivative compounds have been shown to exert anticancer mechanisms in the human body. I3C has been shown to exhibit direct anti-estrogenic activity via competitive inhibition of estrogen receptors; up-regulate the cytochrome P450 isoenzymes CYP1A1, CYP1A2 and CYP1B1, thereby increasing estrogen metabolism; shift estrogen metabolism away from the more proliferative (16-OHE1) towards the more protective (2-OHE1) estrogen species; induce cancer cell apoptosis via NF κ β pathways; inhibit cancer cell growth at the G1 stage; and increase the expression of p21, p27 and p53 tumor suppressors. The use of I3C for the prevention and treatment of breast, endometrial, colon, and prostate cancers as well as for the treatment of herpes simplex virus (HSV) and human papillomavirus (HPV), including cervical dysplasia and cervical cancer, has been studied in depth in both animals and humans with favourable results.

Quantity

60 capsules per bottle

Dose

Take 1–3 capsules daily or as directed by your licensed health care practitioner.

Potential side effects/Safety

No side effects or adverse events have been reported at regular therapeutic
dosages. In doses exceeding 800 mg per day, oral administration of I3C may
cause reversible symptoms of tremor, nausea and imbalance or unsteadiness.

References

"Show references"

"Hide references"

1. “Indole-3-carbinol – Monograph”, Alternative Medicine Review 10, no. 4 (2005): 337–342.
2. Fan, S, Q. Meng, K. Auborn, T. Carter, and E.M. Rosen. “BRCA1 and BRCA2 as molecular targets for phytochemicals
indole-3-carbinol and genistein in breast and prostate cancer cells”, British Journal of Cancer 94, no. 3 (2006): 407–426.
3. Rogan, E.G. “The Natural chemopreventive compound indole-3-carbinol: State of the science”, In vivo 20, no. 2
(2006): 221–228.
4. Michnovicz, J.J., H. Adlercreutz, and H.L. Bradlow. “Changes in levels of urinary estrogen metabolites after oral
indole-3-carbinol treatment in humans”, Journal of the National Cancer Institute 89, no. 10 (1997): 718–723.
5. Nachshon-Kedmia, M., S. Yannai, A. Hajb, and F.A. Fares. “Indole-3-carbinol and 3,3 -diindolylmethane induce
apoptosis in human prostate cancer cells”, Food and Chemical Toxicology 41, issue 6 (2003): 745–752.
6. Chinni, S.R. Y. Li, S. Upadhyay, P.K. Koppolu, and F.H. Sarkar. “Indole-3-carbinol (I3C) induced cell growth inhibition,
G1 cell cycle arrest and apoptosis in prostate cancer cells”, Oncogene 20, no. 23 (2001): 2927–2936.
7. Zhang, J., J.C. Hsu, M.A. Kinseth, L.F. Bjeldanes, and G.L. Firestone. “Indole-3-carbinol induces a G1 cell cycle arrest
and inhibits prostate-specific antigen production in human LNCaP prostate carcinoma cells”, Cancer 98, no. 11
(2003): 2511–2520.
8. Hsu, J.C., J. Zhang, A. Dev, A. Wing, L.F. Bjeldanes, and G.L. Firestone. “Indole-3-carbinol inhibition of androgen
receptor expression and downregulation of androgen responsiveness in human prostate cancer cells”,
Carcinogenesis 26, no. 11 (2005): 1896–1904.
9. Frydoonfar, H.R., D.R. McGrath, and A.D. Spigelman. “The effect of indole-3-carbinol and sulforaphane on a prostate
cancer cell line”, ANZ Journal of Surgery 73, no. 3 (2003): 154–156.
10. Minich, D.M. and J.S. Bland. “A review of the clinical efficacy and safety of cruciferous vegetable phytochemicals”,
Nutrition Reviews 65, no. 6 (2007): 259–267.
11. Reed, G.A., K.S. Peterson, H.J. Smith, J.C. Gray, D.K. Sullivan, M.S. Mayo, J.A. Crowell, and A. Hurwitz. “A Phase I study
of indole-3-carbinol in women: Tolerability and effects”, Cancer Epidemiology, Biomarkers & Prevention 14 (2005):
1953–1960.
12. Aggarwal, B.B. and H. Ichikawa. “Molecular targets and anticancer potential of indole-3-carbinol and its derivatives”,
Cell Cycle 4, no. 9 (2005): 1201–1215.
13. Sarkar, F.H. and Y. Li. “Indole-3-carbinol and prostate cancer”, The Journal of Nutrition 134, no. 12 (2004):
3493S–3498S.
14. Ashok, B.T., Y. Chen, X. Liu, H.L. Bradlow, A. Mittelman, and R.K. Tiwari. “Abrogation of estrogen-mediated cellular
and biochemical effects by indole-3-carbinol”, Nutritrion and Cancer 41, no. 1–2 (2001): 180–187.
15. Auborn, K.J., S. Fan, E.M. Rosen, L. Goodwin, A. Chandraskaren, D.E. Williams, D.Z. Chen, and T.H. Carter. “Indole-3-
carbinol is a negative regulator of estrogen”, The Journal of Nutrition 133, no. 7 (2003): 2470S–2475S.
16. Meng, Q., F. Yuan, I.D. Goldberg, E.M. Rosen, K. Auborn, and S. Fan. “Indole-3-carbinol is a negative regulator of
estrogen receptor-alpha signaling in human tumor cells”, The Journal of Nutrition 130, no. 12 (2000): 2927–2931.